Revisioning Bio

Precision repurposing for overlooked clinical assets.

We identify shelved or underprioritized drugs and redirect them toward diseases where the pathway, biomarkers, and regulatory path are stronger.

Our Approach Strategic Inquiries

Shelved clinical assets Prior human data can create a faster starting point than traditional discovery.

Pathway-driven indications Failed oncology assets can still have value when biology maps to another disease.

Biomarker-enriched trials We use measurable biology to select patients and confirm target engagement.

505(b)(2)-oriented development Where justified, existing data may reduce duplication and support a lean clinical bridge.

The Model

Biotech does not always need to start from zero.

Many drugs are shelved after failing in one indication because of trial design, patient selection, endpoints, competitive pressure, or commercial fit. Revisioning Bio looks for the better match.

Find stranded science

We search for assets with real evidence, known pharmacology, and an overlooked path forward.

Reposition by mechanism

We map drug activity to diseases where inflammation, metabolism, or immune signaling may drive pathology.

Validate with precision

We use biomarkers, AI-supported diligence, and university research networks before major capital spend.

Interactive biology map

A pathway-level view of inflammation, metabolism, depression biology, and the gut-brain axis.

Systems Biology

Precision Psychiatry

Applying oncology discipline to neurological disease.

Pathway first Start with biology, not broad symptom categories.

Biomarker selected Enroll patients most likely to express the target pathway.

Target engagement Use pharmacodynamic readouts to show the drug is doing what it should.

Lean clinical bridge Advance toward focused Phase 1b/2a validation where existing data supports the path.

Investor & Strategic Inquiries

Unlocking value from clinical assets others left behind.

Revisioning Bio partners around repurposed therapeutics, precision biomarkers, university-enabled validation, and capital-efficient clinical translation.

Contact